{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T04:27:25Z","timestamp":1785212845024,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T00:00:00Z","timestamp":1542499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genetic testing capability and guidelines are rapidly expanding to assess inherited prostate cancer (PCA). Clinical genetic data from multigene testing can provide insights into the germline pathogenic variant (PV) spectrum and correlates in men with PCA unselected for metastatic disease to optimize identification of men for genetic evaluation and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cross\u2010sectional analysis was conducted of de\u2010identified clinical genetic testing data from a large commercial genetic testing laboratory in the US. ICD\u201010 claims codes were used to identify men with PCA, along with family history data. Gleason score was abstracted from test request forms. Overall PV rate among men with PCA was estimated, along with PVs in DNA repair genes. Family history and Gleason score association to germline DNA repair PVs was assessed using Fisher's exact test with correction for false\u2010discovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of August 2017, genetic results were available on 1328 men with PCA. Overall PV rate was 15.6%, with 10.9% of PV in DNA repair genes. PVs were most commonly identified in\n                      <jats:italic>BRCA2<\/jats:italic>\n                      (4.5%),\n                      <jats:italic>CHEK2<\/jats:italic>\n                      (2.2%),\n                      <jats:italic>ATM<\/jats:italic>\n                      (1.8%), and\n                      <jats:italic>BRCA1<\/jats:italic>\n                      (1.1%). Breast cancer family history was significantly associated with germline DNA repair PVs (OR 1.89, [95%CI 1.33, 2.68],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003). Among men with Gleason score&gt;=\u20096 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009706), Gleason&gt;\u2009=\u20098 was significantly associated with DNA repair PVs (OR 1.85 [95%CI 1.22, 2.80],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A substantial proportion of men with PCA unselected for metastatic disease carry germline DNA repair PVs. Breast cancer family history and high Gleason score are important predictors to identify men with PCA who may carry germline DNA repair PVs. Our findings support current NCCN guidelines and have implications for genetic assessment, therapeutic management, and cascade testing for men with PCA and their families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.23739","type":"journal-article","created":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T22:29:49Z","timestamp":1542580189000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing"],"prefix":"10.1002","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-5913","authenticated-orcid":false,"given":"Veda N.","family":"Giri","sequence":"first","affiliation":[{"name":"Cancer Risk Assessment and Clinical Cancer Genetics Division of Population Science, Department of Medical Oncology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hegarty","sequence":"additional","affiliation":[{"name":"Division of Biostatistics Department of Pharmacology and Experimental Therapeutics Sidney Kimmel Medical College Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Hyatt","sequence":"additional","affiliation":[{"name":"Cancer Risk Assessment and Clinical Cancer Genetics Division of Population Science, Department of Medical Oncology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"O'Leary","sequence":"additional","affiliation":[{"name":"Invitae San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Garcia","sequence":"additional","affiliation":[{"name":"Invitae San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology Department of Medical Oncology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard G.","family":"Gomella","sequence":"additional","affiliation":[{"name":"Department of Urology Thomas Jefferson University Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,11,18]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate (Version 4. 2018). Accessed (August 23 2018 athttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf)."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1173"},{"key":"e_1_2_8_4_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High\u2010risk Assessment: Breast and Ovarian (Version 2.2019). (Accessed August 13 2018 athttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf)."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603144"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00039","article-title":"Inherited pathogenic variants in males undergoing multigene panel testing for prostate cancer\u2014Emerging implications for personalized PCA genetic evaluation","volume":"1","author":"Giri VN","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11137"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt074"},{"key":"e_1_2_8_10_1","first-page":"2015","article-title":"PD\u20101 Blockade in Tumors with Mismatch\u2010Repair Deficiency","volume":"372","author":"Le DT","journal-title":"NEJM"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.1882"},{"key":"e_1_2_8_13_1","unstructured":"Genetics of Prostate Cancer (PDQ\u00ae). National Cancer Institute. [Accessed April 29 2018]. Available at:https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-genetics-pdq&#160."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604132"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.11.033"},{"key":"e_1_2_8_16_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Prostate Cancer Early Detection (Version 1.2018). [Accessed April 29 2018]. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/prostate_detection.pdf"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy035"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.6908"},{"key":"e_1_2_8_19_1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Colorectal Cancer Screening (Version 1.2018). Available athttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colorectal_screening.pdf."},{"key":"e_1_2_8_20_1","first-page":"JCO684316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing","author":"Balma\u00f1a J","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_21_1","first-page":"1339","article-title":"Gene panel testing for inherited cancer risk","volume":"12","author":"Hall MJ","year":"2014","journal-title":"JNCCN"},{"key":"e_1_2_8_22_1","unstructured":"ASCO Practice Guidelines: Panel Tests. [Accessed April 29 2018]. Available at:https:\/\/www.asco.org\/practice\u2010guidelines\/cancer\u2010care\u2010initiatives\/genetics\u2010toolkit\/genetic\u2010testing\/panel\u2010tests."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.004"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23739","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:07:20Z","timestamp":1775272040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,18]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/pros.23739"],"URL":"https:\/\/doi.org\/10.1002\/pros.23739","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,18]]},"assertion":[{"value":"2018-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}